Biotech RadarJobs updated

COMPANY

Invivyd

HQ: New Haven, CT source · invivyd.com ↗ · New England

Clinical Phase 3

13 open jobs · last seen Oct 23, 2026 · 11 sources

Location: New Haven, CT · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: COVID-19 SARS-CoV-2 VYD2311 ADG20 VYD222 VYD2311-SD VYD2311-MD VYD222 (pemivibart)

Since the raise (Nov 17, 2025): 13 of 13 open jobs were first seen after it.

13Open jobs$182.5MRaised (2 yrs)8Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Strategic Account Manager, BostonRemote (Boston)Oct 13, 2026Oct 14, 2026
Field Reimbursement ManagerRemote (DC, NJ, Maryland)Oct 6, 2026Oct 9, 2026
Senior Vice President, Technical OperationsNew Haven, CTOct 6, 2026Oct 9, 2026
Senior Director, Strategic IDNs and Health System AccessRemoteSep 30, 2026Oct 9, 2026
Senior Virology Care Specialist/Strategic Account Manager, North FloridaRemote (North Florida) Sep 24, 2026Oct 9, 2026

See all 13 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (13 open jobs at last check). source ↗
  2. Trial start Phase 3: Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine source ↗
  3. Trial start Phase 3: Study of VYD2311 for the Prevention of COVID-19 source ↗
  4. Raise Follow-on offering: $125M (total, as published), announced Nov 17, 2025. Source: SEC filing. source ↗
  5. Raise Follow-on offering: $57.5M (total, as published), announced Aug 22, 2025. Source: SEC filing. source ↗
  6. Debt Debt: $30M (not counted as a raise), announced Apr 21, 2025. Source: SEC filing. source ↗
  7. Trial start Phase 1: A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants source ↗
  8. Trial start Phase 3: A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2 source ↗
  9. Trial start Phase 1: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants source ↗
  10. Trial start Phase 2/Phase 3: Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19 source ↗
  11. Trial start Phase 2/Phase 3: Evaluation of ADG20 for the Prevention of COVID-19 source ↗

Open jobs 13

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Strategic Account Manager, BostonRemote (Boston)Oct 13, 2026Oct 14, 2026Mid
Field Reimbursement ManagerRemote (DC, NJ, Maryland)Oct 6, 2026Oct 9, 2026Senior
Senior Vice President, Technical OperationsNew Haven, CTOct 6, 2026Oct 9, 2026Executive
Senior Director, Strategic IDNs and Health System AccessRemoteSep 30, 2026Oct 9, 2026Senior
Senior Virology Care Specialist/Strategic Account Manager, North FloridaRemote (North Florida) Sep 24, 2026Oct 9, 2026Senior
Regional Sales Director, MidwestRemote (Chicago, Minneapolis, St. Louis, Kansas City)Sep 14, 2026Oct 9, 2026Senior
Regional Sales DirectorRemote (Philadelphia or Washington D.C.)Aug 14, 2026Oct 9, 2026Senior
Senior Virology Care Specialist/Strategic Account Manager, ConnecticutRemote (Connecticut)Jul 1, 2026Oct 9, 2026Senior
Strategic Account Manager, Los AngelesRemote (Los Angeles)Jun 3, 2026Oct 9, 2026Mid
Senior Virology Care Specialist, KentuckyRemote (Kentucky)Feb 27, 2026Oct 9, 2026Senior
Director, Thought Leader LiaisonBoston, MaFeb 20, 2026Oct 15, 2026Senior
Director, Thought Leader Liaison, West CoastLos Angeles, California (West Coast Preferred)Dec 11, 2025Oct 9, 2026Senior
Vice President, Associate General Counsel, Infectious Disease FranchiseNew Haven, CT (Northeast preferred)Apr 18, 2025Oct 9, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $182.5M · Debt: $30.0M. Last 2 years.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT07655180Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccinePhase 3RecruitingJun 8, 20262026-08 (estimated)
NCT07298434Study of VYD2311 for the Prevention of COVID-19Phase 3Active, not recruitingJan 8, 20262026-08 (estimated)
NCT06039449A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2Phase 3CompletedSep 8, 2023Nov 19, 2024 (actual)
NCT06523153A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy ParticipantsPhase 1Active, not recruitingAug 28, 20242025-05 (estimated)
NCT04859517Evaluation of ADG20 for the Prevention of COVID-19Phase 2/Phase 3TerminatedApr 27, 2021Nov 4, 2022 (actual)
NCT06004128Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other TreatmentsNot listedNo longer availableNot listedNot listed
NCT05791318A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult ParticipantsPhase 1CompletedMar 28, 2023May 8, 2024 (actual)
NCT04805671Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19Phase 2/Phase 3TerminatedJul 26, 2021Feb 10, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Invivyd on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback